November 18, 2026 · American heart journal · DOI: 10.1016/j.ahj.2026.107663

Selective serotonin reuptake inhibitors And Depression in Atrial Fibrillation: Design of the SAD-AF Randomized Controlled Trial.

Listen to this summary

This randomized, single-blind trial asks whether escitalopram, an SSRI antidepressant, improves quality of life, reduces atrial fibrillation (AF) burden, and lowers AF-related hospital presentations in patients with paroxysmal or persistent AF and depressive symptoms (PHQ-9 ≥8), compared with placebo added to standard care. The primary outcome is the AFEQT quality-of-life score in 154 planned participants, with AF burden measured via wearable or implanted-device monitoring and autonomic function assessed through blood pressure and heart rate variability.

Y Koh, L Lu, L Chen, S K Das, S Virk, D Liang, U Thakur, R D Anderson, A Al-Kaisey, G Lee, B Pathik, A McLellan, J Morton, A Voskoboinik, SandersP, C G Davey, P Kistler, J Kalman, McG Wong

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play